RxDoctor Payments Data

James Park, DO

Neurology · Newport Beach, CANPI 1114276854

Payments from drug & device makers

$61,947in general payments, 2019–2025

Across 301 payments — averaging $205.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$57K
  • UCB, Inc.$1K
  • Sunovion Pharmaceuticals Inc.$833
  • AbbVie$561
  • Neurelis, Inc.$405
  • Neuropace, Inc.$404
  • plus $2K from 21 others

What the payments were for

  • Speaking & faculty fees$16,80064%
  • Travel & lodging$2,4779%
  • Food & beverage$6,78026%
  • Education$1190%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,947 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$99,504
Medicare patients
193
Services billed
499

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate115$282,053
EpidiolexCannabidiol (Cbd)11$278,869
BriviactBrivaracetam51$186,075
NayzilamMidazolam39$79,970
AptiomEslicarbazepine Acetate31$67,491
Lamictal XrLamotrigine13$32,745
UbrelvyUbrogepant12$18,484
Lacosamide75$7,750
Levetiracetam ErLevetiracetam75$6,140
Levetiracetam131$5,936
Carbamazepine ErCarbamazepine16$2,487
Gabapentin64$2,044
Memantine Hcl23$1,619
Lamotrigine ErLamotrigine16$1,528
Zonisamide52$1,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$56,811$282,053115 claims
UCB, Inc.Briviact, Nayzilam$1,107$266,04690 claims
Sunovion Pharmaceuticals Inc.Aptiom$833$67,49131 claims
AbbVieUbrelvy$561$18,48412 claims
Upsher-smith Laboratories LLCTopiramate$23$55322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →